Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis

Hepatology Research

Volumn 41, Issue 10, 2011, Pages 955-964

  Watanabe, Sumio ^a   Enomoto, Nobuyuki ^b   Koike, Kazuhiko ^c   Izumi, Namiki ^d   Takikawa, Hajime ^e   Hashimoto, Etsuko ^f   Moriyasu, Fuminori ^g   Kumada, Hiromitsu ^h   Imawari, Michio ⁱ  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alanine aminotransferase; Chronic hepatitis C virus; Hepatocellullar carcinoma; Pegylated inteferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; JAPAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 80053233149     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00847.x     Document Type: Article

References (22)

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50years in Japan. Intervirology 2010; 53: 39-43.
2. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62 (Suppl 1): 8-17.
3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44 (Suppl XIX): 102-7.
4. Hamada H, Yatsuhashi H, Yano K etal. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331-9.
5. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
7. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
8. Iino S, Okita K, Omata M, Kumada H, Hayashi N, Tanikawa K. Clinical efficacy of PEG-interferon α-2b and ribavirin combination therapy for 48weeks in chronic hepatitis C patients with genotype 1 and high viral load - retrospective comparison with interferon α-2b and ribavirin combination therapy for 24weeks. Kantansui 2004; 49: 1099-121.
9. Nagase Y, Yotsuyanagi H, Okuse C etal. Effect of treatment with interferon α-2b and ribavirin in patients infected with genotype 2 hepatitis C virus. Hepatol Res 2008; 38: 252-8.
10. Watanabe S, Enomoto N, Koike K etal. Prolonged treatment with pegylated interferon α-2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2010; 40: 135-44.
11. Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2010; 8: 884-90.
12. Sezaki H, Suzuki F, Akuta N etal. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009; 52: 43-8.
13. Moriyama M, Matsumura H, Aoki H etal. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int 2005; 25: 85-90.
14. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-94.
15. Arase Y, Ikeda K, Suzuki F etal. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23.
16. Kurokawa M, Hiramatsu N, Oze T etal. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009; 39: 432-8.
17. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50: 387-92.
18. Cardoso AC, Moucari R, Figueiredo-Mendes C etal. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
19. Morgan TR, Ghany MG, Kim HY etal. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
20. Arase Y, Ikeda K, Suzuki F etal. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007; 79: 1485-90.
21. Tanaka A, Uegaki S, Kurihara H etal. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-7.
22. Radkowski M, Gallegos-Orozco JF, Jablonska J etal. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-14.